Galderma's Nemluvio Demonstrates Rapid Relief From Itch Within 48 Hours, New Clinical Analysis Reveals

Galderma Group AG has published comprehensive post-hoc analyses from its major clinical trial programs, revealing that Nemluvio delivers measurable improvements in itching and sleep quality within just two days for patients suffering from chronic skin conditions. The research data, presented through analyses of the ARCADIA and OLYMPIA trial programs, was published in the Journal of the European Academy of Dermatology and Venereology.

Swift Clinical Response: What The Data Shows

The clinical findings demonstrate notably faster therapeutic responses than placebo. In patients with atopic dermatitis treated with nemolizumab, itch intensity declined by approximately 10.7% within 48 hours, significantly outpacing the 2.9% reduction observed in the placebo group. The contrast becomes even more pronounced in prurigo nodolaris patients, where nemolizumab achieved a 17.2% reduction in itch compared to just 3.7% with placebo.

Sleep disturbances, a major quality-of-life concern for these patients, showed similarly encouraging trends. Nemolizumab improved sleep outcomes by 9.9% in atopic dermatitis within two days, versus 4.6% for placebo. Among prurigo nodolaris patients, the therapeutic advantage was even greater, with a 13.4% improvement compared to 4.3% in the control group.

Understanding The Patient Population

Atopic dermatitis and prurigo nodolaris represent chronic dermatological challenges marked by severe itching and inflammatory skin manifestations. The ARCADIA trial program enrolled more than 1,700 patients across two identically designed studies, evaluating nemolizumab administered via subcutaneous injection every four weeks alongside standard topical corticosteroids and calcineurin inhibitors in adolescents and adults 12 years and older with moderate-to-severe atopic dermatitis. The 16-week initial treatment phase provided robust efficacy and safety data.

The OLYMPIA program consisted of two parallel pivotal phase III trials involving 560 patients with moderate-to-severe prurigo nodolaris, conducted over 16 and 24 weeks respectively, comparing nemolizumab monotherapy to placebo.

Sustained Response Through Day 14

By day 14 of treatment, the momentum continued. Approximately one-quarter of atopic dermatitis patients and more than one-third of prurigo nodolaris patients achieved clinically meaningful and significant responses across both itch and sleep metrics. Daily assessments utilizing the Peak Pruritus Numerical Rating Scale and Sleep Disturbance Numerical Rating Scale documented these improvements.

Market Authorization And Commercial Performance

Nemluvio secured FDA approval for adults with prurigo nodolaris in August 2024, followed by clearance for patients 12 years and older with moderate-to-severe atopic dermatitis in December 2024. Originally developed by Chugai Pharmaceutical Co., Ltd., nemolizumab is marketed globally under the Nemluvio brand by Galderma, excluding Japan and Taiwan, where Maruho Co., Ltd. commercializes it as Mitchga.

Commercial traction has been notable. Net sales of Nemluvio for the first nine months of 2025 reached $263 million. This strong performance prompted Galderma to significantly raise its full-year guidance to 17.0-17.7%, up from the previously projected 12-14%, reflecting confidence in the product’s market trajectory.

GALDERMA GROUP shares are currently trading at 160.50 Swiss francs, down 0.93% on the day.